Shots:

• Teva to get an exclusive right to commercialize Tuznu in Israel- leveraging its marketing capabilities and experience in bringing pharmaceutical products to market and will be responsible for local registration- sales- and marketing in Israel
• Prestige will assume responsibility for product registration with the EMA and commercial supply of Tuznue from its manufacturing facilities in Osong- Korea
• Tuznue is biosimilar referencing Roche’s Herceptin (trastuzumab)- used to treat HER2-overexpressing BC & m-gastric adenocarcinoma. Additionally- the EMA has accepted an MAA for Tuznue based on the global clinical trial results

 ­ Ref: BusinessWire | Image: BioSpectrum Asia